Detecting Depression and Bipolar Disorder in Adolescents Using a Biomarker Panel
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 75
- 试验地点
- 1
- 主要终点
- Biomarker for Major Depressive Disorder (MDD) and Bipolar Disorder in Adolescents
研究概览
简要总结
Depression and bipolar disorder are major public health concerns for adolescents today. Teenage depression and bipolar disorder are associated with social isolation, family stress, school failure, substance abuse and suicide. Screening for depression and bipolar disorder so that treatment can be started early in the course of illness is an urgent public health priority. Many teens with bipolar disorder are incorrectly diagnosed as having unipolar depression. It is critical that adolescents receive proper screening and assessment that leads to an accurate diagnosis and treatment. An efficient, cost-effective, blood-based screening program could be performed on an annual or semi-annual basis to potentially detect depression and then differentiate between unipolar and bipolar depression. If this type of screening were able to detect a significant percentage of teens with depression or bipolar disorder, the positive impact on U.S. public health would be substantial. The purpose of this study is to conduct a pilot study to assess the probability of detecting adolescent unipolar and bipolar depression through blood samples.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 13 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- •Exclusion of Major Depressive Disorder and Bipolar Disorder Participants:
- •Meet the DSM-IV criteria for substance abuse or dependence in the last month
- •History of fainting or other significant adverse event during blood draws in the past
- •Daily use of oral or inhaled steroids
- •High risk of suicidal behaviors, homicidal behaviors, or self-harm
- •A medical condition, such as Addison's Disease, which is highly likely to influence the inflammatory or HPA responses
- •Exclusion of Healthy Control Participants:
- •Clinically significant psychiatric or substance abuse disorder
- •Unstable medical or neurological illness
- •History of fainting or other significant adverse event during blood draws in the past
- •Daily use of oral or inhaled steroids
- •A medical condition, such as Addison's Disease, which is highly likely to influence the inflammatory or HPA responses
结局指标
主要结局
Biomarker for Major Depressive Disorder (MDD) and Bipolar Disorder in Adolescents
时间窗: 4 years
The MDDScore™ will determine the biomarker of Major Depressive Disorder (MDD) and Bipolar Disorder. The MDDScore™ is determined using nine blood based biomarkers (inflammatory markers \[4\], stress related hormones \[2\], neuroendocrine \[1\] and metabolic proteins \[2\]) on physiological pathways related to MDD. The test results for the MDDScore™ range from 1 to 10. If the patient's score is 1, the patient has a less than 10% likelihood of having MDD. If the patient's MDDScore™ is 10, the patient has a greater than 90% likelihood of having MDD. An MDDScore™ of 5 or less is considered normal or negative and a score of 6 or more is considered "diseased" or positive. This same scoring system would hold true for classifying the likelihood of having bipolar disorder, as well. Test characteristics, such as sensitivity and specificity, are calculated based on this determination.
次要结局
未报告次要终点